Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2003

View Archived Issues

NN-703 may be effective in adults with moderately severe GH deficiency

Antiviral and spermicidal agent WHI-05 in development

NXC-4720 generates positive data in validation studies

Improved vision in extension phase of Lucentis wet AMD study

Development of AS-1403 discontinued following phase I biodistribution results

Findings from DAC:GLP-1 studies reported

Vical and Merck & Co. amend license agreement

Medtronic to commercialize rhBMP-2 in Japan

Novel telomerase inhibitors covered by Cancer Research Technology patent

New mGluR5 antagonists in early development at Merck

Boehringer Igelheim describes new glucocorticoid receptor modulators and their use

Novel pyridazinone-based p38 kinase inhibitors prepared by Pharmacia researchers

Bayer scientists prepare and test new gamma-secretase inhibitors for AD therapy

DakoCytomation and Northwest Biotherapeutics to develop prostate cancer diagnostics

Zengen drug delivery technology used for oral strip products

Meditech and Elan extend joint venture

Phase II Campath trial in MS makes progress

TZE-5323: a potential therapeutic drug for the long-term treatment of endometriosis

Synthetic progestins with high tissue and receptor selectivity

PHA-927F reported to be a potent and selective inhibitor of tissue factor/factor VIIa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...